Do analysts recommend INDP or ALT?

Altimmune has a consensus target price of $14.33, indicating a potential upside of 343.76%. Given Altimmune's stronger consensus rating and higher possible upside, analysts clearly believe Altimmune is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Altimmune 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media prefer INDP or ALT?

In the previous week, Altimmune had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Altimmune's score of 0.27 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INDP or ARVN?

Arvinas has a consensus price target of $14.17, suggesting a potential upside of 52.17%. Given Arvinas' stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arvinas 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.45

Does the media favor INDP or ARVN?

In the previous week, Arvinas had 8 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Arvinas and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Arvinas' score of 1.35 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INDP or EIKN?

Eikon Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 128.10%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eikon Therapeutics 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has better earnings & valuation, INDP or EIKN?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A

Is INDP or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -302.89% -203.49% Eikon Therapeutics N/A N/A N/A

Does the media prefer INDP or EIKN?

In the previous week, Eikon Therapeutics had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Eikon Therapeutics' score of 0.91 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CAPR or INDP more profitable?

Capricor Therapeutics' return on equity of -56.60% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Indaptus Therapeutics N/A -302.89% -203.49%

Does the media refer more to CAPR or INDP?

In the previous week, Capricor Therapeutics had 47 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 48 mentions for Capricor Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Capricor Therapeutics' score of 0.11 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INDP or CABA?

Cabaletta Bio has a consensus target price of $15.33, indicating a potential upside of 340.61%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger earnings & valuation, INDP or CABA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is INDP or CABA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -302.89% -203.49% Cabaletta Bio N/A -128.27% -95.47%

Does the media prefer INDP or CABA?

In the previous week, Cabaletta Bio had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Cabaletta Bio's score of 0.57 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Indaptus Therapeutics (INDP) Competitors

$1.16 -0.01 (-0.85%)

As of 09/3/2026 04:00 PM Eastern

Compare

INDP vs. ALT, ARVN, EIKN, CAPR, and CABA

Should you buy Indaptus Therapeutics stock or one of its competitors? Indaptus Therapeutics's main competitors and comparable companies include Altimmune (ALT), Arvinas (ARVN), Eikon Therapeutics (EIKN), Capricor Therapeutics (CAPR), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Indaptus Therapeutics compare to Altimmune?

Indaptus Therapeutics (NASDAQ:INDP) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Indaptus Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Indaptus Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-302.89%	-203.49%
Altimmune	-214,860.98%	-31.41%	-26.96%

Indaptus Therapeutics has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A
Altimmune	$40K	15,707.49	-$88.09M	-$0.78	N/A

In the previous week, Altimmune had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Altimmune's score of 0.27 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Altimmune has a consensus target price of $14.33, indicating a potential upside of 343.76%. Given Altimmune's stronger consensus rating and higher possible upside, analysts clearly believe Altimmune is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Altimmune beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Arvinas?

Indaptus Therapeutics (NASDAQ:INDP) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Arvinas had 8 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Arvinas and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Arvinas' score of 1.35 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indaptus Therapeutics has higher earnings, but lower revenue than Arvinas. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A
Arvinas	$262.60M	2.29	-$80.80M	$0.10	93.10

Arvinas has a net margin of 2.94% compared to Indaptus Therapeutics' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-302.89%	-203.49%
Arvinas	2.94%	1.91%	1.29%

Indaptus Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Arvinas has a consensus price target of $14.17, suggesting a potential upside of 52.17%. Given Arvinas' stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

Arvinas beats Indaptus Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Eikon Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, Eikon Therapeutics had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Eikon Therapeutics' score of 0.91 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 128.10%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

7.1% of Indaptus Therapeutics shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Eikon Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-302.89%	-203.49%
Eikon Therapeutics	N/A	N/A	N/A

Summary

Eikon Therapeutics beats Indaptus Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Capricor Therapeutics had 47 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 48 mentions for Capricor Therapeutics and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Capricor Therapeutics' score of 0.11 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Capricor Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Capricor Therapeutics' return on equity of -56.60% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Indaptus Therapeutics has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	24.23	-$105.04M	-$2.45	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

Capricor Therapeutics presently has a consensus target price of $29.15, suggesting a potential upside of 214.12%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Capricor Therapeutics beats Indaptus Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Cabaletta Bio?

Indaptus Therapeutics (NASDAQ:INDP) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Indaptus Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market.

Cabaletta Bio's return on equity of -128.27% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-302.89%	-203.49%
Cabaletta Bio	N/A	-128.27%	-95.47%

Cabaletta Bio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Cabaletta Bio has a consensus target price of $15.33, indicating a potential upside of 340.61%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Cabaletta Bio had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.38 beat Cabaletta Bio's score of 0.57 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cabaletta Bio beats Indaptus Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$155.89M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.18	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	12.89	16.29	12.89	6.14
Net Income	-$20.85M	-$22.72M	$3.47B	$349.01M
7 Day Performance	1.75%	0.34%	0.60%	-0.27%
1 Month Performance	-14.71%	8.52%	5.73%	0.68%
1 Year Performance	-74.84%	52.66%	25.35%	14.84%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	0.6105 of 5 stars	$1.16 -0.9%	N/A	-78.5%	$155.89M	N/A	N/A	6	Positive News
ALT Altimmune	2.3428 of 5 stars	$3.28 +6.1%	$14.33 +337.0%	-12.2%	$601.06M	$40K	N/A	50
ARVN Arvinas	3.5217 of 5 stars	$9.59 +3.3%	$14.17 +47.7%	+17.8%	$598.76M	$262.60M	95.91	420	Positive News
EIKN Eikon Therapeutics	3.6664 of 5 stars	$11.38 +4.6%	$25.00 +119.7%	N/A	$589.32M	N/A	N/A	384	News Coverage
CAPR Capricor Therapeutics	3.0801 of 5 stars	$9.89 -1.2%	$29.15 +194.7%	+47.8%	$581.97M	$22.27M	N/A	101	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. ALT, ARVN, EIKN, CAPR, and CABA

How does Indaptus Therapeutics compare to Altimmune?

Summary

How does Indaptus Therapeutics compare to Arvinas?

Summary

How does Indaptus Therapeutics compare to Eikon Therapeutics?

Summary

How does Indaptus Therapeutics compare to Capricor Therapeutics?

Summary

How does Indaptus Therapeutics compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. ALT, ARVN, EIKN, CAPR, and CABA

How does Indaptus Therapeutics compare to Altimmune?

Which has more volatility & risk, INDP or ALT?

Is INDP or ALT more profitable?

Which has preferable earnings and valuation, INDP or ALT?

Does the media prefer INDP or ALT?

Do analysts recommend INDP or ALT?

Do institutionals & insiders have more ownership in INDP or ALT?

Summary

How does Indaptus Therapeutics compare to Arvinas?

Do insiders and institutionals hold more shares of INDP or ARVN?

Does the media favor INDP or ARVN?

Which has better valuation & earnings, INDP or ARVN?

Is INDP or ARVN more profitable?

Which has more volatility and risk, INDP or ARVN?

Do analysts recommend INDP or ARVN?

Summary

How does Indaptus Therapeutics compare to Eikon Therapeutics?

Does the media prefer INDP or EIKN?

Do analysts recommend INDP or EIKN?

Do insiders & institutionals believe in INDP or EIKN?

Which has better earnings & valuation, INDP or EIKN?

Is INDP or EIKN more profitable?

Summary

How does Indaptus Therapeutics compare to Capricor Therapeutics?

Does the media refer more to CAPR or INDP?

Do insiders and institutionals believe in CAPR or INDP?

Which has more volatility & risk, CAPR or INDP?

Is CAPR or INDP more profitable?

Which has better valuation and earnings, CAPR or INDP?

Do analysts rate CAPR or INDP?

Summary

How does Indaptus Therapeutics compare to Cabaletta Bio?

Do institutionals and insiders believe in INDP or CABA?

Which has more volatility & risk, INDP or CABA?

Is INDP or CABA more profitable?

Which has stronger earnings & valuation, INDP or CABA?

Do analysts prefer INDP or CABA?

Does the media prefer INDP or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools